| T cell ageing: effects of age on development, survival & function N Salam, S Rane, R Das, M Faulkner, R Gund, U Kandpal, V Lewis, ... Indian Journal of Medical Research 138 (5), 595-608, 2013 | 169 | 2013 |
| Inducible nitric oxide synthase in T cells regulates T cell death and immune memory M Vig, S Srivastava, U Kandpal, H Sade, V Lewis, A Sarin, A George, ... The Journal of clinical investigation 113 (12), 1734-1742, 2004 | 140 | 2004 |
| MK2: a novel molecular target for anti-inflammatory therapy S Duraisamy, M Bajpai, U Bughani, SG Dastidar, A Ray, P Chopra Expert opinion on therapeutic targets 12 (8), 921-936, 2008 | 87 | 2008 |
| T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab U Bughani, A Saha, A Kuriakose, R Nair, RB Sadashivarao, ... PloS one 12 (7), e0180088, 2017 | 54 | 2017 |
| Molecular targeting of E3 ligases–a therapeutic approach for cancer M Lakshmanan, U Bughani, S Duraisamy, M Diwan, S Dastidar, A Ray Expert Opinion on Therapeutic Targets 12 (7), 855-870, 2008 | 33 | 2008 |
| Pentoxifylline functions as an adjuvant in vivo to enhance T cell immune responses by inhibiting activation-induced death R Suresh, M Vig, S Bhatia, EPB Goodspeed, B John, U Kandpal, ... The Journal of Immunology 169 (8), 4262-4272, 2002 | 27 | 2002 |
| Naive CD4 T cells from aged mice show enhanced death upon primary activation H Mattoo, M Faulkner, U Kandpal, R Das, V Lewis, A George, S Rath, ... International immunology 21 (11), 1277-1289, 2009 | 24 | 2009 |
| Recent patents reveal microtubules as persistent promising target for novel drug development for cancers U Bughani, S Li, HC Joshi Recent patents on anti-infective drug discovery 4 (3), 164-182, 2009 | 15 | 2009 |
| Chemoprevention of familial adenomatous polyposis by bromo‐noscapine (EM011) in the ApcMin/+ mouse model S Li, AM Ghaleb, J He, U Bughani, AB Bialkowska, VW Yang, HC Joshi International journal of cancer 131 (6), 1435-1444, 2012 | 12 | 2012 |
| Noscapinoids: A new class of anticancer drugs demand biotechnological intervention HC Joshi, A Salil, U Bughani, P Naik Medicinal plant biotechnology, 303-320, 2010 | 10 | 2010 |
| Enhanced soluble production of biologically active recombinant human p38 mitogen-activated-protein kinase (MAPK) in Escherichia coli SK Khattar, P Gulati, PK Kundu, V Singh, U Bughani, M Bajpai, KS Saini Protein and Peptide Letters 14 (8), 756-760, 2007 | 10 | 2007 |
| LewisV N Salam, S Rane, R Das, M Faulkner, R Gund, U Kandpal Mattoo H., Prabhu S., Ranganathan V., Durdik J., George A., RathS., Bal V …, 2013 | 6 | 2013 |
| Use of a CD6 binding partner and method based thereon P Nair, R Melarkode, BS Manian, A Barve, U Bughani, JEM Casimiro US Patent 10,189,899, 2019 | 4 | 2019 |
| 874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy SR Boreddy, R Nair, A Banerjee, A Kuriakose, PK Pandey, C Dey, M Shri, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 3 | 2021 |
| BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGFβ signaling to durably suppress tumor growth SR Boreddy, R Nair, PK Pandey, A Kuriakose, SB Marigowda, C Dey, ... Cancer Research 83 (11), 1883-1904, 2023 | 2 | 2023 |
| Use of itolizumab to reduce phosphorylation of cd6 P Nair, A Saha, RB Sadashivarao, U Bughani, R Melarkode US Patent App. 16/387,442, 2019 | 2 | 2019 |
| Immunotherapy methods using anti-PD-L1 antibodies in combination with EGFR1 targeted-TGF-beta immunomodulatory fusion proteins N Govindappa, SP Srinivasa, U Bughani, N Reshmi US Patent 11,060,097, 2021 | 1 | 2021 |
| Use of a CD6 binding partner and method based thereon P Nair, R Melarkode, BS Manian, A Barve, U Bughani, JEM Casimiro US Patent 11,028,168, 2021 | 1 | 2021 |
| Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab U Bughani, A Saha, A Kuriakose, R Nair, RB Sadashivarao, ... Plos one 13 (1), e0192335, 2018 | 1 | 2018 |
| Use of itolizumab to reduce phosphorylation of cd6 P Nair, A Saha, RB Sadashivarao, U Bughani, R Melarkode US Patent App. 18/335,542, 2024 | | 2024 |
